IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
APG-2575 is a novel, orally administered small-molecule Bcl-2‒selective inhibitor. APG-2575 is designed to treat hematologic malignancies and solid tumors by selectively blocking antiapoptotic protein Bcl-2 to restore the normal apoptosis process in cancer cells.
| Clinical Trial | Status | Age Group |
|---|---|---|
| A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Recruiting | 18 years and older |
AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.
